Arkaitz Imaz1, Jordi Niubó2, Mackenzie L Cottrell3, Emilia Perez4, Angela D M Kashuba3, Juan M Tiraboschi1, Sandra Morenilla1, Benito Garcia1, Daniel Podzamczer1. 1. Human Immunodeficiency Virus and Sexually Transmitted Infections Unit, Department of Infectious Diseases. 2. Department of Microbiology, Hospital Universitari de Bellvitge-Bellvitge Biomedical Research Institute, L'Hospitalet de Llobregat, Barcelona, Spain. 3. Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill. 4. Laboratori Clínic L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain.
Abstract
BACKGROUND: This study assessed the penetration and efficacy of tenofovir alafenamide (TAF) in the male genital tract (MGT) and the semen quality of individuals infected with human immunodeficiency virus (HIV)-1 who were treated with a TAF-containing regimen. METHODS: This was a prospective, open-label, single-arm study of 14 virologically-suppressed, HIV-1-infected men on stable antiretroviral therapy with elvitegravir, cobicistat, emtricitabine (E/C/F) and tenofovir disoproxil fumarate (TDF) who switched to E/C/F and TAF. At baseline (pre-switch) and at 12 weeks post-switch, we measured HIV-1 RNA in seminal plasma (SP) and blood plasma (BP), tenofovir (TFV) in SP and BP, and TFV-diphosphate (dp) in peripheral blood mononuclear cells (PBMCs) and seminal mononuclear cells (SMCs) at the end of the dosing interval (C24h). Semen quality was assessed before switching and after 12 weeks on TAF. RESULTS: With TAF, TFV C24 was 11.9-fold higher in SP than in BP. This concentration was significantly lower than TFV C24 in SP with TDF, but 9.6-fold higher than the 50% inhibitory concentration (IC50) (11.5 ng/mL). By contrast, the median TFV-dp concentration achieved with TAF in SMCs was 6% that of TFV-dp in PBMCs. The TFV-dp SMC:PBMC ratio was also significantly lower with TAF. Nonetheless, TFV-dp C24 in SMC was comparable with TAF and TDF. All the patients had HIV-1 RNA <40 copies/mL in BP and SP at baseline and at 12 weeks post-switch. No significant differences were observed in semen quality between TAF and TDF. CONCLUSIONS: Extracellular and intracellular seminal TFV distribution differs between TAF and TDF. Nevertheless, both formulations, combined with elvitegravir/cobicistat/emtricitabine, maintained HIV-1 RNA suppression in semen. Differences in MGT distribution were not associated with differences in semen quality. CLINICAL TRIALS REGISTRATION: EudraCT: 2016-001371-69.
BACKGROUND: This study assessed the penetration and efficacy of tenofovir alafenamide (TAF) in the male genital tract (MGT) and the semen quality of individuals infected with human immunodeficiency virus (HIV)-1 who were treated with a TAF-containing regimen. METHODS: This was a prospective, open-label, single-arm study of 14 virologically-suppressed, HIV-1-infectedmen on stable antiretroviral therapy with elvitegravir, cobicistat, emtricitabine (E/C/F) and tenofovir disoproxil fumarate (TDF) who switched to E/C/F and TAF. At baseline (pre-switch) and at 12 weeks post-switch, we measured HIV-1 RNA in seminal plasma (SP) and blood plasma (BP), tenofovir (TFV) in SP and BP, and TFV-diphosphate (dp) in peripheral blood mononuclear cells (PBMCs) and seminal mononuclear cells (SMCs) at the end of the dosing interval (C24h). Semen quality was assessed before switching and after 12 weeks on TAF. RESULTS: With TAF, TFV C24 was 11.9-fold higher in SP than in BP. This concentration was significantly lower than TFV C24 in SP with TDF, but 9.6-fold higher than the 50% inhibitory concentration (IC50) (11.5 ng/mL). By contrast, the median TFV-dp concentration achieved with TAF in SMCs was 6% that of TFV-dp in PBMCs. The TFV-dp SMC:PBMC ratio was also significantly lower with TAF. Nonetheless, TFV-dp C24 in SMC was comparable with TAF and TDF. All the patients had HIV-1 RNA <40 copies/mL in BP and SP at baseline and at 12 weeks post-switch. No significant differences were observed in semen quality between TAF and TDF. CONCLUSIONS: Extracellular and intracellular seminal TFV distribution differs between TAF and TDF. Nevertheless, both formulations, combined with elvitegravir/cobicistat/emtricitabine, maintained HIV-1 RNA suppression in semen. Differences in MGT distribution were not associated with differences in semen quality. CLINICAL TRIALS REGISTRATION: EudraCT: 2016-001371-69.
Authors: Mackenzie L Cottrell; Kuo H Yang; Heather M A Prince; Craig Sykes; Nicole White; Stephanie Malone; Evan S Dellon; Ryan D Madanick; Nicholas J Shaheen; Michael G Hudgens; Jacob Wulff; Kristine B Patterson; Julie A E Nelson; Angela D M Kashuba Journal: J Infect Dis Date: 2016-02-24 Impact factor: 5.226
Authors: Jared M Baeten; Erin Kahle; Jairam R Lingappa; Robert W Coombs; Sinead Delany-Moretlwe; Edith Nakku-Joloba; Nelly R Mugo; Anna Wald; Lawrence Corey; Deborah Donnell; Mary S Campbell; James I Mullins; Connie Celum Journal: Sci Transl Med Date: 2011-04-06 Impact factor: 17.956
Authors: Myron S Cohen; Ying Q Chen; Marybeth McCauley; Theresa Gamble; Mina C Hosseinipour; Nagalingeswaran Kumarasamy; James G Hakim; Johnstone Kumwenda; Beatriz Grinsztejn; Jose H S Pilotto; Sheela V Godbole; Suwat Chariyalertsak; Breno R Santos; Kenneth H Mayer; Irving F Hoffman; Susan H Eshleman; Estelle Piwowar-Manning; Leslie Cottle; Xinyi C Zhang; Joseph Makhema; Lisa A Mills; Ravindre Panchia; Sharlaa Faesen; Joseph Eron; Joel Gallant; Diane Havlir; Susan Swindells; Vanessa Elharrar; David Burns; Taha E Taha; Karin Nielsen-Saines; David D Celentano; Max Essex; Sarah E Hudelson; Andrew D Redd; Thomas R Fleming Journal: N Engl J Med Date: 2016-07-18 Impact factor: 91.245
Authors: Joseph J Eron; Chloe Orkin; Joel Gallant; Jean-Michel Molina; Eugenia Negredo; Andrea Antinori; Anthony Mills; Jacques Reynes; Erika Van Landuyt; Erkki Lathouwers; Veerle Hufkens; John Jezorwski; Simon Vanveggel; Magda Opsomer Journal: AIDS Date: 2018-07-17 Impact factor: 4.177
Authors: Chloe Orkin; Jean-Michel Molina; Eugenia Negredo; José R Arribas; Joseph Gathe; Joseph J Eron; Erika Van Landuyt; Erkki Lathouwers; Veerle Hufkens; Romana Petrovic; Simon Vanveggel; Magda Opsomer Journal: Lancet HIV Date: 2017-10-06 Impact factor: 12.767
Authors: Gregory D Huhn; Pablo Tebas; Joel Gallant; Timothy Wilkin; Andrew Cheng; Mingjin Yan; Lijie Zhong; Christian Callebaut; Joseph M Custodio; Marshall W Fordyce; Moupali Das; Scott McCallister Journal: J Acquir Immune Defic Syndr Date: 2017-02-01 Impact factor: 3.731
Authors: Anthony Mills; Jose R Arribas; Jaime Andrade-Villanueva; Giovanni DiPerri; Jan Van Lunzen; Ellen Koenig; Richard Elion; Matthias Cavassini; Jose Valdez Madruga; Jason Brunetta; David Shamblaw; Edwin DeJesus; Chloe Orkin; David A Wohl; Indira Brar; Jeffrey L Stephens; Pierre-Marie Girard; Gregory Huhn; Andrew Plummer; Ya-Pei Liu; Andrew K Cheng; Scott McCallister Journal: Lancet Infect Dis Date: 2015-11-02 Impact factor: 25.071
Authors: Stephen A Greene; Jingxian Chen; Heather M A Prince; Craig Sykes; Amanda P Schauer; Kimberly Blake; Julie A E Nelson; Cynthia L Gay; Myron S Cohen; Julie B Dumond Journal: Clin Pharmacol Ther Date: 2019-05-31 Impact factor: 6.875